243 related articles for article (PubMed ID: 27056325)
1. Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition.
Ghosh S; Taylor A; Chin M; Huang HR; Conery AR; Mertz JA; Salmeron A; Dakle PJ; Mele D; Cote A; Jayaram H; Setser JW; Poy F; Hatzivassiliou G; DeAlmeida-Nagata D; Sandy P; Hatton C; Romero FA; Chiang E; Reimer T; Crawford T; Pardo E; Watson VG; Tsui V; Cochran AG; Zawadzke L; Harmange JC; Audia JE; Bryant BM; Cummings RT; Magnuson SR; Grogan JL; Bellon SF; Albrecht BK; Sims RJ; Lora JM
J Biol Chem; 2016 Jun; 291(25):13014-27. PubMed ID: 27056325
[TBL] [Abstract][Full Text] [Related]
2. Controlling Intramolecular Interactions in the Design of Selective, High-Affinity Ligands for the CREBBP Bromodomain.
Brand M; Clayton J; Moroglu M; Schiedel M; Picaud S; Bluck JP; Skwarska A; Bolland H; Chan AKN; Laurin CMC; Scorah AR; See L; Rooney TPC; Andrews KH; Fedorov O; Perell G; Kalra P; Vinh KB; Cortopassi WA; Heitel P; Christensen KE; Cooper RI; Paton RS; Pomerantz WCK; Biggin PC; Hammond EM; Filippakopoulos P; Conway SJ
J Med Chem; 2021 Jul; 64(14):10102-10123. PubMed ID: 34255515
[TBL] [Abstract][Full Text] [Related]
3. CREBBP/EP300 Bromodomain Inhibition Affects the Proliferation of AR-Positive Breast Cancer Cell Lines.
Garcia-Carpizo V; Ruiz-Llorente S; Sarmentero J; González-Corpas A; Barrero MJ
Mol Cancer Res; 2019 Mar; 17(3):720-730. PubMed ID: 30606771
[TBL] [Abstract][Full Text] [Related]
4. CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation.
Garcia-Carpizo V; Ruiz-Llorente S; Sarmentero J; Graña-Castro O; Pisano DG; Barrero MJ
Epigenetics Chromatin; 2018 Jun; 11(1):30. PubMed ID: 29884215
[TBL] [Abstract][Full Text] [Related]
5. Bromodomain inhibition of the coactivators CBP/EP300 facilitate cellular reprogramming.
Ebrahimi A; Sevinç K; Gürhan Sevinç G; Cribbs AP; Philpott M; Uyulur F; Morova T; Dunford JE; Göklemez S; Arı Ş; Oppermann U; Önder TT
Nat Chem Biol; 2019 May; 15(5):519-528. PubMed ID: 30962627
[TBL] [Abstract][Full Text] [Related]
6. Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP.
Wang R; He Y; Robinson V; Yang Z; Hessler P; Lasko LM; Lu X; Bhathena A; Lai A; Uziel T; Lam LT
Mol Cancer Ther; 2018 Dec; 17(12):2543-2550. PubMed ID: 30266801
[TBL] [Abstract][Full Text] [Related]
7. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.
Hay DA; Fedorov O; Martin S; Singleton DC; Tallant C; Wells C; Picaud S; Philpott M; Monteiro OP; Rogers CM; Conway SJ; Rooney TP; Tumber A; Yapp C; Filippakopoulos P; Bunnage ME; Müller S; Knapp S; Schofield CJ; Brennan PE
J Am Chem Soc; 2014 Jul; 136(26):9308-19. PubMed ID: 24946055
[TBL] [Abstract][Full Text] [Related]
8. CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms.
Castillo J; Wu E; Lowe C; Srinivasan S; McCord R; Wagle MC; Jayakar S; Edick MG; Eastham-Anderson J; Liu B; Hutchinson KE; Jones W; Stokes MP; Tarighat SS; Holcomb T; Glibicky A; Romero FA; Magnuson S; Huang SA; Plaks V; Giltnane JM; Lackner MR; Mounir Z
Cancer Res; 2019 Aug; 79(15):3916-3927. PubMed ID: 31182547
[TBL] [Abstract][Full Text] [Related]
9. Structure-Based Design of Highly Selective Inhibitors of the CREB Binding Protein Bromodomain.
Denny RA; Flick AC; Coe J; Langille J; Basak A; Liu S; Stock I; Sahasrabudhe P; Bonin P; Hay DA; Brennan PE; Pletcher M; Jones LH; Chekler ELP
J Med Chem; 2017 Jul; 60(13):5349-5363. PubMed ID: 28375629
[TBL] [Abstract][Full Text] [Related]
10. Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.
Romero FA; Taylor AM; Crawford TD; Tsui V; Côté A; Magnuson S
J Med Chem; 2016 Feb; 59(4):1271-98. PubMed ID: 26572217
[TBL] [Abstract][Full Text] [Related]
11. Targeted degradation of the enhancer lysine acetyltransferases CBP and p300.
Vannam R; Sayilgan J; Ojeda S; Karakyriakou B; Hu E; Kreuzer J; Morris R; Herrera Lopez XI; Rai S; Haas W; Lawrence M; Ott CJ
Cell Chem Biol; 2021 Apr; 28(4):503-514.e12. PubMed ID: 33400925
[TBL] [Abstract][Full Text] [Related]
12. Structural insight into the recognition of acetylated histone H3K56ac mediated by the bromodomain of CREB-binding protein.
Xu L; Cheng A; Huang M; Zhang J; Jiang Y; Wang C; Li F; Bao H; Gao J; Wang N; Liu J; Wu J; Wong CCL; Ruan K
FEBS J; 2017 Oct; 284(20):3422-3436. PubMed ID: 28815970
[TBL] [Abstract][Full Text] [Related]
13. Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain.
Unzue A; Xu M; Dong J; Wiedmer L; Spiliotopoulos D; Caflisch A; Nevado C
J Med Chem; 2016 Feb; 59(4):1350-6. PubMed ID: 26043365
[TBL] [Abstract][Full Text] [Related]
14. Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.
Zou LJ; Xiang QP; Xue XQ; Zhang C; Li CC; Wang C; Li Q; Wang R; Wu S; Zhou YL; Zhang Y; Xu Y
Acta Pharmacol Sin; 2019 Nov; 40(11):1436-1447. PubMed ID: 31097763
[TBL] [Abstract][Full Text] [Related]
15. Discovery of CREBBP Bromodomain Inhibitors by High-Throughput Docking and Hit Optimization Guided by Molecular Dynamics.
Xu M; Unzue A; Dong J; Spiliotopoulos D; Nevado C; Caflisch A
J Med Chem; 2016 Feb; 59(4):1340-9. PubMed ID: 26125948
[TBL] [Abstract][Full Text] [Related]
16. Development of Dimethylisoxazole-Attached Imidazo[1,2-
Muthengi A; Wimalasena VK; Yosief HO; Bikowitz MJ; Sigua LH; Wang T; Li D; Gaieb Z; Dhawan G; Liu S; Erickson J; Amaro RE; Schönbrunn E; Qi J; Zhang W
J Med Chem; 2021 May; 64(9):5787-5801. PubMed ID: 33872011
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional Profiling of a Selective CREB Binding Protein Bromodomain Inhibitor Highlights Therapeutic Opportunities.
Chekler EL; Pellegrino JA; Lanz TA; Denny RA; Flick AC; Coe J; Langille J; Basak A; Liu S; Stock IA; Sahasrabudhe P; Bonin PD; Lee K; Pletcher MT; Jones LH
Chem Biol; 2015 Dec; 22(12):1588-96. PubMed ID: 26670081
[TBL] [Abstract][Full Text] [Related]
18. Two histone/protein acetyltransferases, CBP and p300, are indispensable for Foxp3+ T-regulatory cell development and function.
Liu Y; Wang L; Han R; Beier UH; Akimova T; Bhatti T; Xiao H; Cole PA; Brindle PK; Hancock WW
Mol Cell Biol; 2014 Nov; 34(21):3993-4007. PubMed ID: 25154413
[TBL] [Abstract][Full Text] [Related]
19. The PHD finger of p300 influences its ability to acetylate histone and non-histone targets.
Rack JGM; Lutter T; Kjæreng Bjerga GE; Guder C; Ehrhardt C; Värv S; Ziegler M; Aasland R
J Mol Biol; 2014 Dec; 426(24):3960-3972. PubMed ID: 25158095
[TBL] [Abstract][Full Text] [Related]
20. The bromodomain: from epigenome reader to druggable target.
Sanchez R; Meslamani J; Zhou MM
Biochim Biophys Acta; 2014 Aug; 1839(8):676-85. PubMed ID: 24686119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]